BofA's analysis is quite crude, basically suggesting Amazon's low pricing will hurt Hims' CAC, which they didn't even bother to estimate, and lead to margin erosion. Well, shldnt expect too much from the sell-side
The thing is, Hims' medication pricing has never been that competitive. GoodRx and
Costplusdrug.com are way cheaper. When Hims was much smaller than Ro, many predicted Ro would crush Hims. But we've seen the market can fit multiple players. BTW Hims not only proved the skeptics wrong but becomes the market share leader.